Business Wire

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents

Share

Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy.

“Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.”

Maestro Agents advance the customer journey from conversational AI to decision-based agentic supply chain orchestration. Unlike generic AI assistants that sit outside the process, Maestro Agents are embedded in live planning environments where they understand context, constraints, and trade-offs to plan with you, not for you. With Maestro Agents now live, Kinaxis will continue to expand the Maestro ecosystem with Maestro Agent Studio (now in limited availability) and the arrival of an agent marketplace in 2026, guiding customers through a phased path to realize the full potential of AI-driven orchestration.

“Today’s supply chains operate within an environment of constant volatility. Resilience and adaptability are no longer aspirational - they are mission-critical,” said Andrew Bell, Chief Product Officer at Kinaxis. “Maestro Agents bring explainable AI into the moments that matter for supply chain leaders and practitioners. As our customers continue to coordinate across processes and grow an ecosystem of Kinaxis and partner-built agents, now they can unlock new levels of speed, resilience, and adaptability.”

Proven Value in Real-World Supply Chains

Early adopters describe Maestro Agents as game-changing by cutting hours of manual work and giving planners confidence to act faster with AI that understands their world.

“Flexibility and guardrails are essential if companies are going to trust and scale AI,” said Eric Thompson, Research Director, IDC. “With Maestro Agents, Kinaxis is showing what practical, explainable AI looks like in enterprise operations by embedding agentic capabilities directly into live planning environments so organizations can test, learn, and grow safely and effectively.”

Built to bring decision intelligence into the moment work happens, Maestro Agents turn analysis into action right inside the planning environment. For supply chain planners, they can now rely on agents to:

  • Bring AI into daily work by analyzing live data, flagging issues, and recommending next-best actions directly within Maestro, helping planners move from problem to decision in seconds.
  • Synthesize and unpack real-world constraints by factoring in supplier capacity, inventory levels, production schedules, and customer priorities to deliver recommendations that are achievable and aligned with business goals.
  • Make AI explainable and trustworthy with human-in-the-loop guardrails and clear reasoning that show why each action is recommended.
  • Free up time for higher-value work by automating reporting and routine analysis, enabling planners to focus on strategic decisions that improve performance and resilience and transforming how planners respond to disruption and make decisions in real time.

Customers are already leveraging the robust capabilities of Maestro Agents, and several enterprise organizations have proven how investments in early innovation are delivering significant real-world value within their supply chain environments:

  • A top-10 global pharmaceutical company boosted planner productivity by up to 10×, cutting the steps to identify inventory risks from 40 clicks to just 4 and surfacing insights in seconds instead of minutes or hours, driving significant efficiency gains across its planning process.
  • One of the world’s largest electronics manufacturers streamlined its reporting processes, cutting manual effort and empowering planners to save over 30 hours per month. With this time back, they were able to focus on higher-value initiatives that improved on-time delivery and elevated customer satisfaction.

These innovations represent the next step toward a connected, adaptive future where AI and human expertise orchestrate the world’s supply chains together.

To learn more about how Maestro Agents can accelerate your supply chain, visit kinaxis.com/aiagents.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities laws, including statements about future product capabilities, planned launches, anticipated benefits, and the expected performance or impact of Kinaxis Maestro Agents. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties are described in Kinaxis’ most recent Annual Information Form and other filings with Canadian securities regulators. Kinaxis disclaims any obligation to update or revise these statements, except as required by law.

Source: Kinaxis Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20251017746583/en/

Contacts

Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye